Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: Patient management considerations

BACKGROUND: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuroprotective effects. In clinical trials, DMF was associated with reduced white blood c...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neurol Clin Pract
Main Authors: Fox, Robert J., Chan, Andrew, Gold, Ralf, Phillips, J. Theodore, Selmaj, Krzysztof, Chang, Ih, Novas, Mark, Rana, Jitesh, Marantz, Jing L.
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2016
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4909524/
https://ncbi.nlm.nih.gov/pubmed/27347439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0000000000000238
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki